Drug industry groups are targeting a Super Bowl ad by telehealth company Hims & Hers, claiming it fails to adequately disclose safety risks associated with its weight loss medications. The ad criticizes the $160 billion weight loss industry and promotes its compounded versions of semaglutide, a medication typically sold under Wegovy and Ozempic.
The Partnership for Safe Medicines, which represents over 40 community and pharmacy groups, has asked the FDA to take action against Hims & Hers’ misleading marketing practices. Pharmaceutical Research and Manufacturers of America (PhRMA) also claims the ad violates federal regulations requiring drug ads not to be false or misleading.
Hims & Hers disputes these claims, stating it’s not a drug manufacturer and follows advertising requirements for telehealth platforms. However, critics argue that the company’s lack of transparency about its compounded drugs’ safety and effectiveness is deceptive.
The FDA has yet to respond to the group’s letters. The dispute highlights the ongoing battle between drug companies marketing lucrative weight loss medications and firms selling less expensive versions made by compounding pharmacies.
Source: https://eu.usatoday.com/story/money/business/2025/02/08/super-bowl-hims-hers-ad-targeted/78289416007